8-K: Oncolytics Launches Phase 2 Colorectal Cancer Study

Oncolytics Biotech Inc. announced the initiation of a randomized Phase 2 study, REO 033, for metastatic colorectal cancer patients, building on previous compelling efficacy data and a recent Fast Track Designation.

Summary

• Oncolytics Biotech Inc. initiated a Phase 2 study, REO 033, for second-line (2L) RAS-mutated, microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients.
• Patients will be randomized to either a control arm (bevacizumab and FOLFIRI) or an experimental arm (pelareorep, bevacizumab, and FOLFIRI).
• The study is powered for statistical significance, with each arm expected to enroll 30 patients, totaling 60 participants.
• All participants will have failed initial platinum-based chemotherapy.
• The primary endpoint of the study is objective response rate (ORR), with progression-free survival (PFS), overall survival (OS), safety, and biomarker analysis as secondary endpoints.
• The trial will be sponsored by Oncolytics, with Dr. Sanjay Goel of Rutgers Cancer Institute of New Jersey serving as the Lead Investigator.
• The company expects to initiate the first study site later in March 2026 and provide preliminary data by the end of 2026.
• The pelareorep-based treatment regimen recently received Fast Track Designation from the U.S. Food & Drug Administration (FDA) for 2L KRAS-mutant, MSS mCRC.
• Previous REO 022 clinical study in this population demonstrated a median OS of 27 months and a median PFS of 16.6 months, substantially exceeding the median 11.2and 5.7-month OS and PFS, respectively, observed for standard-of-care therapy.
• ORR in the REO 022 study was 33% for pelareorep-containing therapy compared to approximately 10% for standard-of-care treatment.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, given the initiation of a statistically powered Phase 2 study, the compelling prior data, and the recent Fast Track Designation, all pointing to significant potential in a large indication.

Positives

• Initiation of a randomized, statistically powered Phase 2 study (REO 033) designed to confirm previous compelling efficacy data in a significant patient population.
• Pelareorep-based treatment regimen recently granted Fast Track Designation by the FDA for 2L KRAS-mutant, MSS mCRC, underscoring its potential in a large and underserved indication.
• Previous REO 022 study demonstrated superior clinical outcomes: median OS of 27 months (vs. 11.2 months for standard-of-care), median PFS of 16.6 months (vs. 5.7 months), and ORR of 33% (vs. ~10%).
• The potential to improve clinical outcomes compared to standard-of-care in the second-line setting could significantly benefit mCRC patients globally.

Risks

• Regulatory outcomes may not be favorable.
• Trial execution could face challenges or delays.
• Availability of financial resources may impact operations.
• Access to capital markets could be limited.
• Market dynamics may shift unfavorably.

Future Outlook

Oncolytics expects to initiate the first study site for REO 033 later in March 2026 and provide preliminary data by the end of 2026. The company believes pelareorep has the potential to significantly improve clinical outcomes compared to standard-of-care in the second-line setting for mCRC patients and is actively pursuing strategic partnerships to accelerate development and maximize commercial impact.

Management Comments

• "I am honored to lead this study as I have a long track record working with pelareorep and have witnessed its ability to improve patient outcomes in a meaningful way." Dr. Sanjay Goel, Lead Investigator.
• "The colorectal cancer data we recorded in the REO 022 study continues to be compelling to this day, as evidenced by the Fast Track Designation, and I hope we can generate additional exciting data in this new trial to support registration." Dr. Sanjay Goel.
• "The potential to improve clinical outcomes compared to the standard-of-care in the second-line setting would have the potential to benefit patients around the world who are affected by colorectal cancer." Dr. Van Morris, Associate Professor at The University of Texas MD Anderson Cancer Center.
• "An immunotherapy with the potential to improve outcomes would improve treatment options in colorectal cancer and would be highly welcomed, especially as we are seeing more and more younger patients being diagnosed with colorectal cancer." Dr. Van Morris.

Industry Context

StockSavvy.ai notes that the initiation of the REO 033 study addresses a significant unmet medical need in second-line RAS-mutant, MSS metastatic colorectal cancer, a large and challenging indication. The focus on immunotherapy with pelareorep aligns with broader industry trends seeking to enhance anti-cancer immune responses, particularly in 'cold' tumors. The Fast Track Designation underscores regulatory recognition of pelareorep's potential to offer a substantial improvement over existing therapies, positioning Oncolytics as a key player in developing novel treatments for advanced gastrointestinal cancers.

Comparison to Industry Standards

• The previous REO 022 clinical study of pelareorep, bevacizumab, and FOLFIRI demonstrated a median Overall Survival (OS) of 27 months, substantially exceeding the median 11.2 months observed for standard-of-care therapy.
• Median Progression-Free Survival (PFS) in REO 022 was 16.6 months, significantly higher than the 5.7 months observed for standard-of-care.
• Objective Response Rate (ORR) in REO 022 was 33% for pelareorep-containing therapy, compared to approximately 10% for standard-of-care treatment.
• Standard-of-care therapy references include Bennouna J. Lancet Oncol (14):29-37, 2013 and Iwamoto S. Ann Oncol. Jul;26(7):1427-33, 2015.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the study confirms previous positive results and leads to regulatory approval and commercialization.
• Patients: Potential for significantly improved treatment options and clinical outcomes for second-line RAS-mutant, MSS metastatic colorectal cancer patients.
• Employees: Continued employment and potential growth opportunities within the company as the drug development progresses.
• Regulatory Authorities: The Fast Track Designation indicates a recognized need for this therapy, potentially streamlining future review processes.

Next Steps

• Initiate the first study site for REO 033 later in March 2026.
• Provide preliminary data from the REO 033 study by year-end 2026.
• Actively pursue strategic partnerships to accelerate development and maximize commercial impact of pelareorep.

Key Dates

Recommendation

The initiation of a randomized Phase 2 study (REO 033) for a large and challenging indication like metastatic colorectal cancer, coupled with previously compelling efficacy data (median OS of 27 months vs. 11.2 months for standard-of-care) and a recent FDA Fast Track Designation, significantly de-risks the development pathway and highlights the substantial commercial potential of pelareorep. This news provides a strong catalyst for future value creation, making it a compelling investment opportunity for seasoned investors.

Keywords

Oncolytics Biotech, ONCY, pelareorep, metastatic colorectal cancer, mCRC, RAS-mutant, KRAS-mutant, microsatellite stable, MSS, immunotherapy, Phase 2 study, REO 033, Fast Track Designation, FDA, oncology, clinical trial, cancer treatment